An observational study in Coronavirus Infection and Hematologic Diseases, sponsored by National Research Center for Hematology, Russia. Completed at 15 sites in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-26.
Sponsored by National Research Center for Hematology, Russia · Observational
This is an observational prospective cohort study to evaluate the clinical course and outcomes of COVID-19 and the underlying disease in patients with hematologic disease (malignant or non-malignant).
This is a web-based registry. After registration, physicians from hematology clinical centers and hospitals in Russia will receive access to the web platform for clinical trial management to fill in the online data collection form in a de-identified manner. This form includes questions about general clinical history of hematologic disease, manifestation, treatment, and the course of COVID-19, concomitant conditions, consequences on the hematologic disease, short-term and long-term outcomes. It will take approximately 10 min to answer the questions. Patients will be followed for 30 days after COVID-19 diagnosis and up to 6 months for hematologic disease outcomes and overall survival assessment.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 666 is above the median of 261 across 3,136 observational studies indexed under COVID-19.
Browse COVID-19 studies →National Research Center for Hematology, Russia is the lead sponsor of 21 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with hematologic disease (both malignant and non-malignant) infected with SARS-CoV-2
Exclusion Criteria
Non-interventional study
30-day all-cause mortality
Rate of death from any cause
Time frame: 30 day
COVID-19 complications
Rate of COVID-19 complications
Time frame: 30 day
ICU admission
Rate of ICU admission
Time frame: 30 day
Mechanical ventilation / O2 requirement
Rate of mechanical ventilation / O2 requirement
Time frame: 30 day
Relapse or progression of hematologic disease
Rate of relapse or progression of hematologic disease
Time frame: 30 day, 90 day and 180 day
Overall survival
Number of patients alive
Time frame: 30 day, 90 day and 180 day
Risk factors
Putative risk factors for the severity and lethality of COVID-19
Time frame: 30 day, 90 day and 180 day
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Research Center for Hematology, Russia